Wells Fargo & Company Raises Heartflow (NASDAQ:HTFL) Price Target to $39.00

Heartflow (NASDAQ:HTFL) had its price objective upped by equities researchers at Wells Fargo & Company from $37.00 to $39.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential downside of 4.26% from the company’s previous close.

HTFL has been the topic of several other research reports. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. William Blair initiated coverage on Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday. Canaccord Genuity Group set a $45.00 price target on Heartflow in a research report on Friday. Finally, Stifel Nicolaus lifted their target price on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Heartflow Stock Performance

Heartflow stock traded up $9.72 during midday trading on Friday, hitting $40.73. 3,975,411 shares of the company’s stock were exchanged, compared to its average volume of 1,434,520. The company has a market cap of $3.51 billion and a P/E ratio of -13.18. The stock has a 50-day moving average price of $28.80 and a two-hundred day moving average price of $27.70. Heartflow has a 52-week low of $20.13 and a 52-week high of $42.95.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. The company’s revenue was up 47.7% compared to the same quarter last year. As a group, sell-side analysts expect that Heartflow will post -0.82 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Campbell Rogers sold 9,219 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $28.34, for a total value of $261,266.46. Following the completion of the sale, the insider directly owned 78,731 shares of the company’s stock, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of Heartflow stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the transaction, the chief executive officer directly owned 457,935 shares in the company, valued at $16,027,725. This represents a 7.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 115,805 shares of company stock worth $3,530,609. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Heartflow

Institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow in the fourth quarter valued at about $27,000. Russell Investments Group Ltd. bought a new stake in Heartflow during the 4th quarter valued at approximately $45,000. Legal & General Group Plc purchased a new position in Heartflow in the 3rd quarter worth approximately $59,000. Essential Partners LLC bought a new position in Heartflow in the 1st quarter worth approximately $57,000. Finally, Strs Ohio purchased a new stake in Heartflow during the 4th quarter valued at approximately $99,000.

Key Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Strong Q2 performance: Heartflow reported a loss of $0.07 per share, beating the $0.22 expected loss by $0.15. Revenue reached $64.08 million, an increase of 47.7% from the prior-year quarter. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Raised 2026 outlook: Management now expects full-year revenue of $246 million to $250 million, well above the approximately $230.1 million analyst consensus. The higher forecast reinforces expectations for continued demand for Heartflow’s AI-based coronary artery disease diagnostic technology.
• Positive Sentiment: Analyst upgrade: Stifel Nicolaus raised its price target from $40 to $45 and upgraded the stock to “Buy,” implying additional upside based on the reported reference price. This adds further momentum following the earnings release. Benzinga
• Neutral Sentiment: Profitability remains a concern: Although the quarterly loss was narrower than expected and significantly improved from the prior year, Heartflow remains unprofitable. Analysts currently expect a full-year loss of approximately $0.82 per share.
• Negative Sentiment: CEO stock sale: Chief Executive John C.M. Farquhar sold 22,562 shares valued at approximately $638,730, reducing his direct holdings by 4.92%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value, but repeated insider selling could still weigh modestly on sentiment. Heartflow CEO Sells Shares

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.